'FabiFlu is the most economical COVID-19 treatment option': Glenmark's reply to Centre on alleged 'overpricing'

In its reply, Glenmark has compared the cost of other therapies approved for emergency use in COVID-19 and argued that a full course treatment with alternatives like Remdesivir, Tocilizumab, and Itolizumab cost three to five times higher than that of Favipiravir.